Clinical trials: Chronic Obstructive Pulmonary Diseases
Asthma
Study to Evaluate the Pharmacokinetic Profile of Salbutamol Delivered by Unit Dose Dry Powder Inhaler (UD-DPI) Compared to the Diskus and Metered Dose Inhaler (MDI) in Healthy Volunteers.
This is an open-label, two part, six period- cross over, randomised, single dose, single centre study in healthy subjects. This is the first clinical study for the UD-DPI. This study is divided into two parts.
- Trial name
- NCT01984086
- Testing
- Salbutamol Sulphate 150mcg UD-DPI Blister(1.6% blend), Salbutamol Sulphate 200mcg UD-DPI Blister(1.6% blend), Salbutamol Sulphate 250mcg UD-DPI Blister(1.6% blend)
- Where
- Australia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Berodual® Respimat® Solution for Inhalation in Patients With Chronic Obstructive Airways Disease
Tolerability, efficacy and handling of Berodual® Respimat® 20/50µg/dose solution for inhalation in patients with chronic obstructive airways disease in daily practice
- Trial name
- NCT02231372
- Testing
- Berodual® Respimat® solution for inhalation
- Volunteers
- 4,602 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
Outcomes in Real-life After Initation of Treatment With Trixeo (Budesonide / Glycopyrronium / Formoterol)
The aim of the CHOROS ORION study is to describe patients' clinical and self-reported outcomes of treatment with BGF in Italy through effectiveness, clinical and self-reported measures assessed pre- and post-treatment initiation…
- Trial name
- CHOROS ORION (NCT05862545)
- Testing
- BGF (budesonide/glycopyrrolate/formoterol fumarate)
- Where
- 20 sites in Italy
- Volunteers
- 250 people
- Sponsor
- AstraZeneca
Chronic Bronchitis
Gala FIH Feasibility Study for the Treatment of Chronic Bronchitis
Feasibility trial (FIH) to assess the safety and clinical utility in patients with chronic bronchitis.
- Trial name
- NCT03107494
- Testing
- Gala Airway Treatment System
- Where
- 2 sites in Austria, Chile
- Volunteers
- 18 people
- Sponsor
- Gala Therapeutics, Inc.
Respiratory Syncytial Virus, Chronic Obstructive Pulmonary Disease, Congestive Heart Failure
An Observational Study to Assess RSV-associated Illness in Adults With COPD and/or CHF
The primary objective of this observational study is to determine the incidence of medically attended (inpatient or outpatient) acute respiratory illnesses or events leading to worsening cardiorespiratory status (ie, acute…
- Trial name
- CD-1089 (NCT01455402)
- Where
- 60 sites in United States, Bulgaria and 7 more
- Volunteers
- 476 people
- Sponsor
- MedImmune LLC
Chronic Graft-versus-host-disease
A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
This study will be conducted to compare the efficacy of axatilimab versus placebo in combination with corticosteroids as initial treatment for moderate or severe chronic graft-versus-host disease (cGVHD).
- Trial name
- AXemplify-357 (NCT06585774)
- Testing
- INCA034176, Corticosteroids
- Where
- 131 sites in United States, Australia and 11 more
- Volunteers
- 240 people
- Sponsor
- Incyte Corporation
Chronic Hepatitis C Genotype 1b
Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Daclatasvir in Treatment-Naїve Patients With Chronic Hepatitis C Genotype 1b
The purpose of this study is to confirm that combination of Narlaprevir, Ritonavir and Daclatasvir is safe and highly effective regimen in treatment-naїve patients with chronic hepatitis C (HCV) genotype 1b infection.
- Trial name
- NCT03485846
- Testing
- Narlaprevir, Ritonavir, Daclatasvir
- Where
- 4 sites in Russia
- Volunteers
- 105 people
- Sponsor
- R-Pharm
Leukaemia
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
The purpose of this study was to confirm the clinical benefit observed in the pivotal registration study, Hx-CD20-406. The Committee for Medicinal Products for Human Use (CHMP) required that a randomized study be conducted in CLL…
- Trial name
- NCT01313689
- Testing
- Ofatumumab, Physicians' Choice
- Where
- 80 sites in Austria, Belgium and 15 more
- Volunteers
- 122 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
TARA Working Prototype [Version 2]: Feasibility Study
TARA is a Digital Behaviour Change Intervention (DBCI) for Individuals with COPD (IwCOPD), which has been designed using a Human-Centred Design (HCD) methodology.
- Trial name
- NCT04320524
- Testing
- Technology-Assisted Respimat Adherence Digital Behaviour Change Intervention
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease, Asthma
Vibration Response Imaging in Chronic Obstructive Pulmonary Disease and Asthma
Obstructive lung disease is usually a differential diagnostic consideration when a patient presents with breathlessness or cough.
- Trial name
- NCT00542282
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Deep Breeze
Hepatitis C Virus Infection
Safety and Efficacy of SOF/VEL/VOX FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis
The primary objective of this study is to evaluate the efficacy, safety, and tolerability of treatment with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) fixed-dose combination (FDC) for 8 weeks and of treatment with…
- Trial name
- POLARIS-3 (NCT02639338)
- Testing
- SOF/VEL/VOX, SOF/VEL
- Where
- 70 sites in United States, Australia and 6 more
- Volunteers
- 220 people
- Sponsor
- Gilead Sciences
Alpha 1-Antitrypsin Deficiency, Emphysema
A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo.
The purpose of this study is to investigate the effect of alvelestat (an oral neutrophil elastase inhibitor) on blood and sputum biomarkers in patients with PiZZ, null or rare variant phenotype/genotype alpha-1 anti-trypsin…
- Conditions
- Alpha 1-Antitrypsin Deficiency, Emphysema, COPD
- Trial name
- ASTRAEUS (NCT03636347)
- Testing
- Alvelestat oral tablet - dose 1, Alvelestat oral tablet - dose 2
- Where
- 26 sites in United States, Belgium and 6 more
- Volunteers
- 99 people
- Sponsor
- Mereo BioPharma
Chronic Obstructive Pulmonary Disease
NVA237 BID Versus Placebo Twelve-week Efficacy Study
The study serves to determine whether the treatment of patients with stable, symptomatic Chronic Obstructive Pulmonary Disease (COPD) with the investigational drug NVA237 is efficient and safe.
- Trial name
- NCT01715298
- Testing
- NVA237
- Where
- 59 sites in United States
- Volunteers
- 432 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
Combivent® HFA-propelled Compared to CFC-propelled Metered Dose Inhaler in Patients With COPD (Chronic Obstructive Pulmonary Disease)
Study to evaluate the safety of combivent delivered in two different formulations (hydrofluoroalkane (HFA) or chlorofluorocarbon (CFC)) from a metered dose inhaler (MDI), using a cumulative dose response model in patients with…
- Trial name
- NCT02182869
- Testing
- Combivent® HFA inhalation aerosol, Combivent® CFC inhalation aerosol
- Volunteers
- 7 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
A Study to Assess the Pulmonary Distribution of Budesonide, Glycopyrronium and Formoterol Fumarate
This study is a 2 treatment period, single dose crossover, gamma scintigraphy study investigating the deposition in the lungs of a Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler.
- Trial name
- NCT03740373
- Testing
- BGF MDI (budesonide, glycopyrronium and formoterol fumarate) with 10 s breath hold, BGF MDI ((budesonide, glycopyrronium and formoterol fumarate) with 3 s breath hold
- Where
- United Kingdom
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
12-week Open-label Evaluation of Efficacy and Safety of Indacaterol
In this 12-week study, patients were randomized to either open-label indacaterol or standard of care for Chronic Obstructive Pulmonary Disease (COPD) treatment; efficacy and safety were assessed.
- Trial name
- MOVE-ON (NCT01232894)
- Testing
- Indacaterol, Long-acting beta2-agonist
- Where
- 8 sites in Israel
- Volunteers
- 90 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease I
The primary objective of this study is to assess the long-term efficacy and safety of once daily treatment of BI 1744 CL inhalation solution (5 and 10 mcg) delivered via the Respimat® inhaler, in patients with COPD.
- Trial name
- NCT00793624
- Testing
- Olodaterol (BI 1744), Formoterol
- Where
- 93 sites in Argentina, Brazil and 18 more
- Volunteers
- 906 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive (COPD)
Evaluation of 611 in Chinese Adults Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
The objective of the study was to evaluate the efficacy and safety of 611 in Chinese adults with moderate to severe COPD.
- Trial name
- NCT07039669
- Testing
- 611
- Where
- 4 sites in China
- Volunteers
- 594 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
COPD
Closed Loop Oxygen Control in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Nasal High Flow in the Hospital
The trial aims to evaluate whether the Airvo 3 device in OptiO2 mode can maintain patients' SpO2 levels within the target range better than manual oxygen titration in hospitalized COPD patients with hypoxemia/respiratory distress.
- Trial name
- NCT07222410
- Testing
- Closed loop oxygen control, Manual titration
- Where
- 4 sites in United States
- Volunteers
- 70 people
- Sponsor
- Fisher and Paykel Healthcare
Pulmonary Disease, Chronic Obstructive
EXACERBATIONS AND REAL-WORLD OUTOMES AMONG PATIENTS WITH COPD INITIATING BREZTRI (EROS+CP Japan Study)
A retrospective real-world data study, assessing the relationship between the timing of Budesonide/Glycopyrrolate/Formoterol initiation following an exacerbation and the occurrence of subsequent exacerbations, severe…
- Trial name
- EROS+CP-Japan (NCT07103642)
- Testing
- BGF
- Where
- United States
- Volunteers
- 3,402 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.